RCUS Q1 2024 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$145M+480.0% YoY

Gross Profit

$145M100.0% margin

Operating Income

-$16M-11.0% margin

Net Income

-$4M-2.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+367.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$6M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$586M

Stockholders' Equity

$707M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$25M	+480.0%
Gross Profit	$145M	$25M	+480.0%
Operating Income	-$16M	-$86M	+81.4%
Net Income	-$4M	-$80M	+95.0%

Revenue Segments

License and Development Services Revenue

$135M93%

Other Collaboration Revenue

$10M7%